# A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

> **NCT03312738** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 159 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Exemestane
- **DRUG:** Everolimus Placebo

## Key facts

- **NCT ID:** NCT03312738
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-15
- **Primary completion:** 2022-04-25
- **Final completion:** 2022-04-25
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312738, "A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03312738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*